T. Rowe Price Associates
SLS icon

T. Rowe Price Associates’s SELLAS Life Sciences SLS Stock Holding History

T. Rowe Price Associates’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.29M Buy
155,066
+32,946
+27% +$227K ﹤0.01% 1937
2026
Q1 		$517K Buy
122,120
+59,094
+94% +$264K ﹤0.01% 2443
2025
Q4 		$238K Buy
63,026
+15,067
+31% +$29.3K ﹤0.01% 2746
2025
Q3 		$78K Hold
47,959
– – ﹤0.01% 2964
2025
Q2 		$106K Buy
+47,959
New +$73.6K ﹤0.01% 2883
2023
Q2 		– Sell
-17,100
Closed -$25K – 2938
2023
Q1 		$25K Hold
17,100
– – ﹤0.01% 2846
2022
Q4 		$40K Hold
17,100
– – ﹤0.01% 2835
2022
Q3 		$35K Hold
17,100
– – ﹤0.01% 2876
2022
Q2 		$38K Hold
17,100
– – ﹤0.01% 2889
2022
Q1 		$114K Hold
17,100
– – ﹤0.01% 2828
2021
Q4 		$95K Buy
17,100
+6,400
+60% +$48.4K ﹤0.01% 2883
2021
Q3 		$98K Sell
10,700
-4,800
-31% -$44.5K ﹤0.01% 2852
2021
Q2 		$172K Sell
15,500
-11,600
-43% -$113K ﹤0.01% 2761
2021
Q1 		$231K Buy
+27,100
New +$222K ﹤0.01% 2641

Other funds holding SLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

T. Rowe Price Associates's SLS Position: Q2 2026 in Review

T. Rowe Price Associates increased its SELLAS Life Sciences (SLS) stake by 27% in Q2 2026, buying an estimated $227K and bringing the position to 155,066 shares worth $2.29M. The position accounts for ﹤0.01% of the portfolio, ranked #1937.

T. Rowe Price Associates first reported a position in SLS in Q1 2021 and has held it in 14 quarters since. 192 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

  • T. Rowe Price Associates held 155,066 shares of SELLAS Life Sciences worth $2.29M as of Q2 2026.
  • T. Rowe Price Associates bought 32,946 SELLAS Life Sciences shares in Q2 2026, an estimated $227K.
  • SELLAS Life Sciences made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1937 holding.
  • T. Rowe Price Associates first reported a position in SELLAS Life Sciences in Q1 2021 and has held it in 14 quarters since.
  • 192 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.